Besides, the authors suggested that LAG-3 expression could be considered for the selection of patients for immunotherapy since LAG-3 overexpression was negatively correlated with survival in patients with NSCLC that had been treated with PD-1 inhibitors, indicating that tumors in which immune evasion is mediated by LAG-3 are less sensitive to PD-1 blockade [123]. Here, LAG3 is linked to non-small cell lung carcinoma.